G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 3.46 EUR
Market Cap: 172.5m EUR
Have any thoughts about
Genfit SA?
Write Note

Gross Margin
Genfit SA

97.4%
Current
92%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.4%
=
Gross Profit
81.8m
/
Revenue
84m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
FR
Genfit SA
PAR:GNFT
172.4m EUR
97%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
142B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country FR
Market Cap 172.4m EUR
Gross Margin
97%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.2B USD
Gross Margin
67%
Country US
Market Cap 142B USD
Gross Margin
60%
Country US
Market Cap 115B USD
Gross Margin
78%
Country US
Market Cap 101.6B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78.5B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Genfit SA
Glance View

Market Cap
172.4m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
28.99 EUR
Undervaluation 88%
Intrinsic Value
Price
G

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.4%
=
Gross Profit
81.8m
/
Revenue
84m
What is the Gross Margin of Genfit SA?

Based on Genfit SA's most recent financial statements, the company has Gross Margin of 97.4%.